Skip to main content
. 2024 Mar 13;15:2254. doi: 10.1038/s41467-024-46490-7

Fig. 6. Sensitivity of SARS-CoV-2 variants to sera of vaccinated and/or infected individuals.

Fig. 6

Neutralization titers of the sera against the indicated viral variants are expressed as ED50. a Neutralizing activity of sera from individuals vaccinated with 3 doses of Pfizer vaccine. Sera (n = 21) were sampled 25–475 days after the third dose. 13/21 had a breakthrough infection at the time of BA.1/2 circulation. b, c. Neutralizing activity of sera from individuals having received the bivalent Wuhan/BA.5 Pfizer boost. Sera were sampled 1 month (b; n = 20) and 6 months (c; n = 14) after the booster dose. d Temporal evolution of Neutralizing Antibody (Nab) titers against D614G, BA.5, EG.5.1.3 and BA.2.86.1 after bivalent Wuhan/BA.5 booster dose. The Nab titers were calculated at the time of injection (month 0) and at the indicated months after injection. e Neutralizing activity of sera from Pfizer-vaccinated recipients after XBB-derived breakthrough infections (infections occurred in September 2023, when XBB-derived variants were predominantly circulating in France). Sera were sampled 10–50 days after the breakthrough (n = 12). The dotted line indicates the limit of detection (ED50 = 30). Each dot represents the mean of n = 2 independent experiments. Black lines represent the median values. Two-sided Friedman test with Dunn’s test for multiple comparisons was performed to compare each viral strain to D614G. 3 doses of Pfizer vaccin: D614G vs. BQ.1.1, p-value = 0.0008; D614G vs. XBB.1, p-value < 0.0001; D614G vs. XBB.1.5, p-value < 0.0001; D614G vs. XBB.1.9.1, p-value < 0.0001; D614G vs. XBB.1.16.1, p-value < 0.0001; D614G vs. XBF, p-value < 0.0001; D614G vs. EG.5.1.3, p-value < 0.0001; D614G vs. BA.2.86.1, p-value < 0.0001. One month after booster dose: D614G vs. BQ.1.1. p-value = 0.0165; D614G vs. XBB.1. p-value < 0.0001; D614G vs. XBB.1.5. p-value = 0.0003; D614G vs. XBB.1.9.1. p-value < 0.0001; D614G vs. XBB.1.16.1. p-value < 0.0001; D614G vs. XBF. p-value < 0.0001; D614G vs. EG.5.1.3. p-value < 0.0001; D614G vs. BA.2.86.1. p-value < 0.0001. Six months after booster dose: D614G vs. BQ.1.1. p-value = 0.0420; D614G vs. XBB.1. p-value < 0.0001; D614G vs. XBB.1.5. p-value < 0.0001; D614G vs. XBB.1.9.1. p-value < 0.0001; D614G vs. XBB.1.16.1. p-value < 0.0001; D614G vs. XBF. p-value = 0.0018; D614G vs. EG.5.1.3. p-value < 0.0001; D614G vs. BA.2.86.1. p-value < 0.0001. After XBB-derived breakthrough infections: D614G vs. XBB.1. p-value = 0.0017; D614G vs. XBB.1.9.1. p-value < 0.0001; D614G vs. XBB.1.16.1. p-value < 0.0001; D614G vs. EG.5.1.3. p-value = 0.0002; D614G vs. BA.2.86.1. p-value = 0.0014. Source data are provided as a Source Data file.